Is Lynparza (Lipadro) chemotherapy or a targeted drug?

Olaparib is a targeted drug rather than a traditional chemotherapy drug. It specifically acts on cancer cells carrying specific gene mutations and is more selective and targeted than chemotherapy drugs.

Olaparib is the first oral polyADP ribose polymerase (PARP) inhibitor that kills cancer cells by inhibiting DNA damage repair enzyme (PARP). This mechanism allows olaparib to show significant efficacy in the treatment of advanced epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer carrying BRCA mutations. In addition, olaparib has also been approved for maintenance treatment after first-line platinum-containing chemotherapy in patients with pancreatic cancer carrying germline BRCA gene mutations, demonstrating its potential in multiple cancer fields.

Unlike traditional chemotherapy drugs, Lynparza does not directly kill all rapidly dividing cells, but targets cancer cells with specific genetic mutations for precise attacks. The advantage of this targeted therapy is that it can reduce damage to normal cells, thereby reducing side effects during treatment.

In clinical trials, olaparib has demonstrated its efficacy and safety. For example, in the POLO study of pancreatic cancer patients with germline BRCA mutations, progression-free survival was significantly improved and the risk of disease progression and death was significantly reduced in the olaparib group compared with the placebo group. These data further confirm the efficacy and potential of olaparib as a targeted drug.

In general, olaparib is an innovative targeted drug that uses a specific mechanism of action to precisely treat cancer cells carrying specific gene mutations. It has demonstrated remarkable efficacy and safety in multiple cancer areas, providing new treatment options for cancer patients.